China-based biopharmaceutical company Canbridge Life Sciences secured $10m yesterday in a series A round that included TF Capital, a venture fund set up by China-based contract research organisation Tigermed.
The round also included venture capital firm Qiming Venture Partners, which focuses on early-stage companies in the media, internet, IT, consumer, retail, healthcare and cleantech sectors.
Canbridge, launched in 2012, signs partnership agreements with biopharmaceutical firms in the west to bring clinical-stage drugs and devices to China and North Asia, and…